Drugs / NYM032
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06383052 | Apr 2024 → Jun 2025 overdue | castration-resistant prostate carcinoma | Norroy Bioscience Co., LTD | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NYM032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06383052 ↗ |
| Modality | Small molecule | “NYM032 is a small molecular with strong affinity for PSMA.” NCT06383052 ↗ |
| Route | Intravenous | “as a intravenous injection dose of 177Lu-NYM032” NCT06383052 ↗ |